eMBR and Axio Partner to Deliver MKLP1 Pro Antibodies for MBR Studies Worldwide

• eMBR Genomics and Axio BioPharma announced the commercial availability of MKLP1 Pro antibodies, enabling global access to key research tools for midbody remnants (MBRs).

• The antibodies hold potential for advancing cancer diagnostics and drug delivery technologies.

eMBR Genomics and Axio BioPharma have partnered to introduce MKLP1 Pro antibodies, marking their first global commercial release. These antibodies, developed from extensive research into midbody remnants (MBRs), are designed to support advancements in cancer research and diagnostics.

MBRs, large extracellular vesicles produced during cell division, were once considered cellular debris. Recent discoveries, spearheaded by eMBR co-founder Dr. Ahna Skop, reveal that MBRs play a significant role in cellular communication and could be instrumental in cancer detection. Dr. Skop explained, “MBRs contain RNA and active translation…making these antibodies widely available opens up this frontier to researchers worldwide.”

The MKLP1 Pro antibodies, available in IgM and IgG formats, are unique in targeting MBRs. This capability positions them as essential tools for identifying actively dividing cells, potentially enabling earlier and more accurate cancer diagnoses.

“Our partnership with eMBR Genomics is a testament to our shared mission of accelerating scientific discovery and improving patient outcomes,” said Justin Byers, CEO of Axio BioPharma. The collaboration leverages Axio’s manufacturing expertise to ensure researchers globally can access these diagnostic tools.

eMBR CEO Roman Gelman highlighted the significance of this partnership, noting, “These antibodies represent decades of critical research in midbody biology…we believe, will soon be the new standard in early cancer and disease screening.”

This strategic alliance combines eMBR’s innovations with Axio’s global distribution network, potentially reshaping the landscape of cancer diagnostics and treatment research.